

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited taken responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



泰 達

天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code : 8189)

RESULTS OF ANNUAL GENERAL MEETING

The Board is pleased to announce that all the resolutions as set out in the notice of AGM dated 31 April 2026 were duly passed at the AGM held on 22 May 2026.

RESULTS OF THE AGM

Reference is made to the notice of an annual general meeting (the “AGM”) of the Company (the “Notice”) dated 30 April 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice. The board of directors of the Company is pleased to announce that all the resolutions as set out in the Notice were duly passed by way of poll at the AGM held on 22 May 2026.

As at the date of the AGM, the Company had 2,133,900,000 shares in issue including 697,500,000 domestic shares and 1,436,400,000 H shares. Shareholders of the Company holding a total of 665,215,000 shares of the Company were entitled to attend and vote for or against all the resolutions set out in the Notice by way of poll at the AGM. There were no shares entitling the shareholders of the Company to attend and vote only against any of the resolutions at the AGM.

Details of the poll result in respect of resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		Number of Shares Represented by Votes (%)		Total Number of Shares
		For	Against	
1.	To consider and, if thought fit, approve the audited consolidated accounts of the Group for the year ended 31 December 2025.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares
2.	To consider and, if thought fit, approve the report of the directors of the Company.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares
3.	To consider and, if thought fit, approve the report of the Supervisory Committee of the Company.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares
4.	To consider and, if thought fit, approve the proposal of appointing Fan, Chan & Co. Limited as auditor of the Company for the financial year of 2026 and authorize the Directors of the Company to fix their remuneration.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares
SPECIAL RESOLUTION [#]				
5.	To grant to the Board a general mandate to issue, allot and deal with additional Domestic Shares/H Shares not to exceed 20% of Domestic Shares in issue and 20% of H Shares in issue of the Company, and to authorise the Board to make such amendments to the articles of association of the Company as it thinks fit so as to reflect the new share capital structure subsequent to allotment or issue of additional Shares.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares
6	Article 91 to the Articles of Association be amended upon having obtained the approval of the Shareholders of the Company and the fulfillment of filing requirements with the Administration of Industry and Commerce and to grant Specific Mandate (as defined in the Circular) to the Board of Directors of the Company.	665,215,000 shares 100%	0 shares 0%	665,215,000 shares

[#] The description of this resolution is by way of summary only. The full text appears in the Notice of the AGM of the Company for the year 2025.

As more than half of the votes present at the AGM either in person or by proxy were cast in favour of the above ordinary resolutions numbered (1) to (4), these resolutions were duly passed as ordinary resolutions.

As more than two-thirds of the votes present at the AGM either in person or by proxy were cast in favour of the above special resolution numbered (5) and (6), this resolution was duly passed as special resolutions.

Ms. Sun Li, Mr. YangZeng and Mr. Xia Alan Zhe as the executive Directors, Mr. He Xin and Mr. Wang Lei; as the non-executive Director and Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang as the independent non-executive Directors attended the AGM.

Peking Certified Public Accountants (中勤萬信會計師事務所), an independent external accountants firm acted as the scrutineer for the purpose of vote-taking at the AGM.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the People's Republic of China
22 May 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. YangZeng and Mr. Xia Alan Zhe; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing and Mr. Wang Lei; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make this announcement or any statement herein misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.